Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 400.61 Mil Enterprise Value: 208.24 Mil PE Ratio: 0 PB Ratio: 1.81 GF Score: 51/100

Lexicon Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 10:40PM GMT
Release Date Price: €5.76 (-0.69%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Our next company presenter -- my name is Jason Gerberry. I'm the U.S. pharma analyst. I'm pleased to be introducing Lexicon Pharmaceuticals. Lonnel Coats, CEO, has a presentation.

So Lonnel, the floor is yours.

Lonnel Coats
Lexicon Pharmaceuticals, Inc. - President, CEO & Director

Thank you, Jason. Thank you very much. Today, I will be making forward-looking statements that may contain risk, all of our risks covered in our SEC filings, which I would suggest you read. I always make these presentations on behalf of the extraordinary men and women at Lexicon who toil daily to advance our medicines in the hands of patients. So let me jump right in.

So Lexicon's scientific platform now has produced 2 commercial products and a pipeline of innovative drugs, the first of which was introduced as XERMELO in 2017 here in the United States and then our collaborator, Ipsen, introduced XERMELO in its territories around the world, more specifically in Europe, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot